Systemic sclerosis: pathogenic mechanisms and their implications for treatment.
Alain Lescoat, Valérie Lecureur, Johann E Gudjonsson...
https://pubmed.ncbi.nlm.nih.gov/41217519/Actively Recruiting
Led by GlaxoSmithKline · Updated on 2026-09-08
300
Participants Needed
134
Research Sites
8 weeks
Total Duration
Researchers are evaluating the efficacy and safety of belimumab compared to placebo, both given alongside standard therapy, for adults with systemic sclerosis associated interstitial lung disease SSc-ILD. The study aims to assess how belimumab affects lung function and other disease features such as skin thickening and symptoms like fatigue that influence quality of life. Participants will be randomly assigned to receive either belimumab or a placebo, both in addition to their usual therapy. Belimumab is given by subcutaneous injection. The study measures various health outcomes at baseline and after 52 weeks, including lung capacity, skin condition, fatigue, and disease progression. Throughout the study, participants will undergo scans, lung function tests, skin assessments, and questionnaires about symptoms and quality of life. Researchers will monitor adverse events and disease markers to evaluate treatment impact and safety over the 52-week period.
CONDITIONS
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
GlaxoSmithKline
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Belimumab plus standard therapy | Placebo plus standard therapy | Standard‑of‑care (mycophenolate) |
|---|---|---|---|
| What it is | Belimumab, a monoclonal antibody targeting B‑lymphocyte stimulator, given subcutaneously alongside existing standard therapy for SSc‑ILD | Placebo injection administered alongside standard therapy in the comparator arm | Mycophenolate mofetil is recommended therapy for SSc‑ILD in current clinical guidelines |
| Role in trial | Investigational treatment arm under study | Control arm receiving placebo | Represents current standard care for informing clinical context |
| Primary purpose | To assess whether adding belimumab slows lung function decline in SSc‑ILD | Serves as placebo control to isolate belimumab effect | Used in routine care to preserve or improve lung function in SSc‑ILD |
| How it is given or performed | Subcutaneous injection of belimumab added to background therapy | Subcutaneous placebo injection added to background therapy | Oral medication taken as continuous immunosuppression under standard care |
| Evidence status | Efficacy and safety are under evaluation in an ongoing randomized placebo‑controlled trial | Used to isolate treatment effect; no independent efficacy supporting its use | Supported by high‑quality guideline evidence for preserving lung function in SSc‑ILD |
| Important risks | Safety profile under study; belimumab known to carry immunosuppression risks in other diseases | Placebo expected to have no direct pharmacologic risk, but patients continue standard therapy risks | Mycophenolate can cause immunosuppression‑related side effects such as infection risk |
| Important limitations | Unknown whether belimumab adds benefit beyond standard therapy with mycophenolate; results awaited | Placebo arm does not reflect active comparator, limits direct clinical relevance | While guideline‑recommended, mycophenolate may not fully halt ILD progression in all patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 52 weeks
Participants receive either belimumab or placebo injections, both alongside standard therapy, to evaluate their effects on lung and skin symptoms.
Regular visits during the 52 weeks
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Alain Lescoat, Valérie Lecureur, Johann E Gudjonsson...
https://pubmed.ncbi.nlm.nih.gov/41217519/GlaxoSmithKline
Lead Sponsor